

**INITIATION OF COVERAGE****Dave Storms, CFA**[Dave@stonegateinc.com](mailto:Dave@stonegateinc.com)

214-987-4121

**Market Statistics** in AUD

Price	\$ 0.05
52 week Range	\$0.02 - \$0.08
Daily Vol (3-mo. average)	1,426,080
Market Cap (M)	\$ 81.0
Enterprise Value (M)	\$ 81.2
Shares Outstanding: (M)	1,366.6
Float (M)	1,152.8
Public Ownership	80.4%
Institutional Ownership	3.9%

**Financial Summary** in AUD


Cash (M)	\$ 4.3
Cash/Share	\$ 0.00
Debt (M)	\$ -
Equity (M)	\$ 13.9
Equity/Share	\$ 0.01

FYE: Jun	2022	2023E	2024E
----------	------	-------	-------

(all figures in M, expect per share information)

Rev	\$ 4.3	\$ 15.7	\$ 24.9
Chng%	123%	65%	58%
EBITDA	\$ (7.3)	\$ 1.5	\$ 9.3
Net Income	\$ (11.8)	\$ (2.9)	\$ 3.2
EPS	\$ (0.86)	\$ (0.21)	\$ 0.22

EV/Revenue	12.1x	6.6x	4.0x
EV/EBITDA	-5.1x	-28.2x	14.9x
P/E	0.0x	-0.2x	0.2x

**COMPANY DESCRIPTION**

BluGlass Limited ("BLG" or "the Company") is an Australian and US based laser diode manufacturer that specializes in visible light, or Gallium Nitride (GaN), lasers. BluGlass offers a full suite of end-to-end laser diode services that includes design, fabrication, and packaging capabilities that can range from off-the-shelf products to unique customized products. The Company supports this with vertically integrated manufacturing capabilities at its fabrication centers located in Fremont, California, Nashua, New Hampshire, and Sydney, New South Wales. BluGlass Limited was originally established in 2006 after spinning out from Macquarie University. In the same year, the company was listed on the Australian Stock Exchange under the ticker symbol "BLG".

**BLUGLASS LIMITED (ASX: BLG)****COMPANY UPDATES**

**2H23 Results:** BluGlass ended FY23 with revenues of A\$9.5M, an increase of 123% year over year. This was primarily revenue from R&D grants of A\$8.3M, up 148% from the prior year. Most notable was the addition of revenue from laser diode sales, which the Company did not have in FY22. We expect that BLG will see a significant increase in laser diode revenues over the coming quarters as it increases manufacturing capabilities. We believe that BLG is well positioned as a pure play GaN laser provider to grow its portfolio and capitalize on the GaN laser systems market that is expected to reach \$2.5B by 2025.

**Strong Partnerships:** BLG has strong partnerships across a number of different institutions, both public and private. On the public side BLG is partnering with Ganvix to develop Vertical Cavity Surface Emitting Lasers (VCSELs) with the goal of bringing commercial viability to green wavelength lasers. The Company is also in partnerships with both the University of Santa Barbara California (USBC) and North Carolina State University (NCSU). The partnership with USBC is to bring visible Distributed Feedback (DFB) Lasers to commercial viability, which are lasers that are very narrow in width and high in purity, leading to uses in highly technical applications. The partnership with NCSU is BLG's most recent partnership and is funded by CHIPS Act spending. It is anticipated that these partnerships will help the Company further develop its portfolio.

**Vertical Integration:** In 2022 BLG acquired a purpose-built laser diode fabrication facility located in Silicone Valley. This acquisition quadrupled the wafer capacity and development turns to help meet customer demand. The Silicone Valley facility makes BLG a vertically integrated operation that can be with the customer from design to packaging and testing. By becoming vertically integrated the Company is able to add functionality and increase ASP, while expanding interest among several verticals.

**Current Portfolio:** BLG offers a portfolio of lasers spanning several wavelengths, launched in 2023. This initial cohort of wavelengths included violet at 405nm and 420nm as well as blue at 450nm. BLG shows a rapidly progressing improvement curve with devices already rivaling comparable companies' performance. As the Company continues to innovate, we expect the portfolio to grow and take advantage of the above-mentioned manufacturing capabilities to serve an often-ignored portion of the laser diode market.

**Valuation:** We use a combination of comparative analysis and DCF analysis frame our valuation for BLG. Given the lack of public comparable companies we apply a 60% weighting to our DCF analysis and a 20% weighting to our EV/EBITDA and EV/Revenue ranges. This arrives at a valuation range of A\$0.15 to A\$0.19 with a mid-point of A\$0.17. At an exchange rate of A\$1.58AUD/USD, this is equal to a range of \$0.09 to \$0.12 with a mid-point of \$0.10.

## Business Overview

BluGlass Limited (“BLG” or “the Company”) is an Australian and US based laser diode manufacturer that specializes in visible light Gallium Nitride (GaN) lasers. BluGlass offers a full suite of end-to-end laser diode services that includes design, fabrication, and packaging capabilities that can range from off-the-shelf products to unique customized products. The Company supports this with vertically integrated manufacturing capabilities at its fabrication centers located in Fremont, California, Nashua, New Hampshire, and Sydney, New South Wales.

BluGlass Limited was originally established in 2006 after spinning out from Macquarie University. In the same year, the company was listed on the Australian Stock Exchange under the ticker symbol “BLG”. In 2012, the Company completed its proof-of-concept for the delivery of semiconductor materials grown using its proprietary remote plasma chemical vapor depositions (RPCVD) manufacturing technology. This method is more efficient than the legacy methods of manufacturing, while retaining the scalability of MOCVD. In 2019 the Company launched its direct-to-market GaN laser diode business unit. In 2023 the Company began commercial production of its products and won membership into the Commercial Leap Ahead for Wide-bandgap Semiconductors (CLAWS) Hub, discussed in more detail below. As of 2Q23 BLG holds 53 international patents.

### Exhibit 1: Global Operations




Source: Company Presentation

BLG also offers a complete epitaxial solution for the development and manufacturing of custom nitride templates and device wafers. This offering is through EpiBlu, a service arm and wholly owned subsidiary of the Company. Using EpiBlu’s research and development teams, EpiBlu offers fast prototyping at a cost-effective scale that allows customers to leverage engineers and designs to bring technology and innovation to the market. EpiBlu is being implemented strategically to customers who augment BluGlass product portfolio, such as Ganvix discussed later.

## Market Overview

Lasers are a critical component for several macro trends that are on the cutting edge of technology. The market for lasers is expected to grow to an annualized size of \$25B by 2025 with uses for GaN lasers expected to account for 10% of this market. This is due to the inherent advantages found in GaN lasers as opposed to traditional infrared laser applications, such as superior brightness and higher absorption that contribute to improved precision and cleaner processing. Additionally, the visible and UV light interacts well with both organic materials and quantum materials.

### Exhibit 2: Lasers End Markets



Source: Company Presentation

Of the \$735M addressable market that is expected to be serviced by GaN lasers, BLG expects to have products capable of addressing \$170M of this market by 2025. Of note, industrial applications which require lasers for welding, marking, and 3D printing is forecasted to be a \$400M segment. Scientific product applications, which included quantum computing/sensing and spectroscopy is expected to be an \$100M segment. Biotech which relies on lasers for flow cytometry, DNA sequencing, and photodynamic therapy, is also projected to be a \$60M addressable market.



**Exhibit 3: Target Markets**

Industrial Markets	Scientific Markets	Biotech/Life Science Markets	Display Markets (AR/VR)	Defense - R&D Markets
				
(405nm, 450nm, 525nm)	(405nm, 420nm, 450nm, 490, 525nm)	(405nm, 420nm, 450nm, 490, 525nm)	(450nm, 525nm)	(405nm, 420, 450nm, 488nm, 525nm)
US \$400M	US \$100M	US \$60M	US \$60M	US \$115M

Source: Company Presentation

Given the advantages of GaN Lasers, it is reasonable that the demand will continue to increase for these lasers. However, the supply of these lasers is expected to be challenged at a market wide level due to several factors that are expected to persist. Some of the most notable factors include the high barriers to entry, a lack of focus on GaN lasers from legacy suppliers, and limited flexibility in the market. This supply demand imbalance is expected to continue into the foreseeable future due to the high barriers of entry in the market.

**Exhibit 4: Advantages of GaN Lasers**

	Key Metals	Improvement of energy absorption in metals
Visible light has higher absorption in key industrial metals 	Gold	66x
Cleaner, faster materials processing 	Silver	17x
Tighter beam focus and improved efficiency 	Copper	13x
Higher precision manufacturing, enabling increasingly advanced technology applications 	Aluminium	3x
Visible and UV light interacts favorably with quantum and organic (viruses, bacteria, cancer cells) materials 	Nickel	1.5x
	Steel	1.5x

Source: Company Presentation


We note that BLG is well positioned to take advantage of the above-mentioned market dynamics. With a history of innovation and R&D spending, BluGlass is a provider of choice to serve the GaN laser market. As this market continues to evolve and grow, we expect BLG to continue expanding its product offerings to fully service this market.

## Offerings

BluGlass is meeting the challenges of providing commercial laser products to a growing market that has few global competitors. Current offerings are focused on both off-the-shelf solutions as well as niche custom solutions. At a high level these offerings serve an often-ignored section of the market and are done in a way that offers significant variations of design, modality, and form to serve a number of unique needs.

To complement the hardware that the lasers are packaged in, BluGlass is also on the leading edge of laser technology. As discussed above, GaN lasers offer a significant advantage over traditional lasers, and by using the RPCVD manufacturing technology BluGlass is able to continuously challenge competition in the manufacturing of GaN lasers. This allows BLG to offer a portfolio of lasers spanning several wavelengths, launched in 2023. This initial cohort of wavelengths included violet at 405nm and 420nm as well as blue at 450nm. BLG shows a rapidly progressing improvement curve with devices already rivaling comparable companies' performance. When this is paired with the RPCVD technology, the Company shows the potential to overtake peers with higher performing and brighter lasers.

Exhibit 5: Overview of BluGlass Hardware



Source: Company Presentation

## Technology Updates

BluGlass' current portfolio covers violet at wavelengths of 397nm, 405nm, and 420nm as well as blue at a wavelength of 450nm. In 2023 the company made significant improvements for power conversion efficiency with 450nm wavelengths improving 55% and 42% in single-mode and multi-mode respectively. This advancement broadens applicable uses to 3D printing, quantum computing, and biotech.

In addition to the efficiency improvements, the Company is also working with Ganvix to develop green GaN lasers in a wavelength of 515nm to 525nm. This is a very impressive technological step as there are currently no green GaN Vertical Cavity Surface-Emitting Lasers (VCSELs) on the market. As part of the agreement BLG brings its RPCVD technology to the table. This technology allows for critical performance advantages for green wavelengths that enable higher power and more efficient power usage.

Exhibit 6: BluGlass Laser Portfolio

	Available for Purchase	Higher-Value Products In Development	Next-gen (premium value/margin) Products in Development
Violet	397nm SM - 200mW*		
	405nm MM - 1W    MM - 3W* SM - 250mW	SM - 300-400mW	SM - 500mW
	420nm MM - 1W    MM - 3W* SM - 250mW	SM - 300-400mW	SM - 500mW
Blue	450nm MM - 1W SM - 100mW	MM - 1.6W    MM - 2.2W    MM - 3.5W SM - 250mW	MM - 5W
	470nm	MM - 2W SM - 100-200mW	
	488nm	SM - 100-200mW	MM - 1.5-2W
Green	525nm	MM - 0.5 - 2W SM - 80-100mW	

Source: Company Presentation

BLG is also partnered with University of Santa Barbara California to bring visible Distributed Feedback (DFB) Lasers to commercial viability. These lasers provide a narrow width with high purity lending to very complex applications, like quantum computing, that require a high degree of precision. Most recently BLG has increased the side-mode suppression ration by more than 50%.

Most recently BLG has won membership into the CLAWS Hub led by North Carolina State University (NCSU). This is one of eight Microelectronic (ME) Commons innovation hubs announced by the US Department of Defense, which is further discussed in detail below. This Hub has six other members, all working towards the goal of creating innovative optoelectronic solutions. The photon technology that is expected to come out of the hub will be applicable to quantum computing, communications, AI, biotechnical, material processing, and defense end markets. This makes the work done in contribution to the Hub using BLG’s RPCVD technology strategically aligned with BluGlass’ commercial goals. The CLAWS Hub is funded with \$39.4M for FY23.

### Manufacturing and Distribution

As discussed in the Market Overview, there are numerous challenges to the global supply of GaN lasers. Critical to this supply challenge is the lack of providers focused on delivering these lasers to market. BLG has taken significant steps to increase its supply capabilities at scale while retaining its innovative edge as well as the high-quality standards of its products through vertically integrating its manufacturing process.


#### Exhibit 4: Challenges to GaN Laser Supply

- X **Challenged by constrained supply** Only a handful of captive global GaN laser suppliers in an emerging market with combined GaN laser systems revenue in excess of \$1B and set to grow to \$2.5B in 2025.
- X **Competitors are largely focused on LEDs** Most competitors are not dedicated GaN laser suppliers; they are captive in larger organizations with large differentiated product portfolios focused on LED and micro-LED markets.
- X **Low mix/high volume business models** Limited form factor flexibility, customisation and manufacturing agility in current business models is creating significant unmet needs in quantum, scientific defence and biotech verticals.
- X **High barriers to market entry**

Source: Company Presentation

In 2022 the Company acquired a purpose-build commercial Silicon Valley laser diode production facility. This acquisition quadrupled the wafer capacity and development turns to help meet customer demand. This vertical integration both increased quality control as well as decreased costs associated with manufacturing thus increasing margins. This purchase was made with \$2.5M, financed in part with a \$3.4M private placement. This is considered a value when compared to the estimated \$40.0M it would cost to build a new facility. This facility complements the facilities located in New Hampshire and New South Wales.

#### Exhibit 4: Manufacturing Process



Source: Company Presentation

BLG continues to distribute directly to OEMs, with customer acquisition initiatives continuing to take hold. BLG will also work with distributors at a regional level in key jurisdictions which include Europe, North America, and Southeast Asia. The Company supplies lower volume higher mix products to these markets. Additionally, BLG will supply development projects to defense and R&D organizations directly.

By leveraging partnerships with Ganvix to develop Vertical Cavity Surface-Emitting Lasers (VCSELs) using BLG’s RPCVD technology as well as the partnership with the University of Santa Barbara California to develop Distributed Feedback Lasers (DFB), the Company is increasing the number of end users served.

**Exhibit 4: CLAWS Hub Lead and Members**

As discussed above, BLG’s most recent partnership with the CLAWS Hub lead by NCSU strategically aligns the Company with peers to innovate in the optoelectronic segment. This partnership is made possible by the creation of the Microelectronics (ME) Commons by the US Department of Defense (DOD). As part of the CHIPS Act the US DoD was allocated \$2.0B dollars to establish the ME Commons program. This program is awarding \$238.0M for FY23 and FY24 among the 8 established regional hubs. Overall, there are 460 members in the program, with the CLAWS Hub that BLG is a member of having 7 members’ total.



Source: Company Presentation

The customer acquisition lifecycle can range from very quick onboarding processes to taking a year or more to complete in the case of very rare and custom projects. For typical engagements, outside of standard projects in standard packages, customers require time to qualify BLG technology for use after the initial discussions. Once the technology is qualified industry standard manufacturing time is 8-12 weeks. This timeframe is extended for niche projects that require advanced or high-powered products due to the length of initial design and qualifications. These longer dated projects can include multiple phases that typically generate revenues throughout the process. Once this process is completed the Company works to turn initial orders into long-term recurring orders.

## Risks

As with any investment, there are certain risks associated with BluGlass' operations as well as with the surrounding economic and regulatory environments common to the laser diode industry.

**Product Development and Launch** – The Company currently operates in a cutting-edge industry. While BLG has a portfolio of lasers, the majority of orders are in the qualification phase. Should the industry change direction, or if the orders do not pass the qualification phase, then product development and launches may need to be repurposed at a significant cost to the Company.

**Liquidity Risk** – As a rapidly growing company, BluGlass regularly reviews its liquidity position in order to ensure sufficient cash flow to support expanding operations and plan for any necessary capital outlays.

**Foreign Exchange Risk** – The Company accounts in Australian dollars. Some of the Company's commitments and expenditures are denominated in U.S. dollars making the Company subject to currency fluctuations. This exposes BluGlass to potential currency fluctuation risk due to translation effects; however, management reviews the exposure on a frequent basis.

**Intellectual Property Laws** – BluGlass currently has a significant number of patents and pending applications for intellectual property that the Company has developed. BluGlass is constantly on guard and ready to defend its intellectual property using litigation if necessary. Should judgements go against the Company this could materially weaken its edge among peers. Additionally, having to pursue litigation as mediation for any infringement could be costly for the Company, regardless of the outcome.

**Research and Development Rebates** – BluGlass derives a material amount of financing from research and development rebates. Any future changes in the laws, regulations, and agreements that surround these rebates could negatively impact the Company's cash flows.

**Earnings and Cash Flows** – The Company has no history of net income, dividends, or cash flow and there can be no assurance that the Company will be profitable going forward. In the case that the Company cannot create enough revenue to sustain on-going business activities, BLG's only source of financing will be through the sale of existing securities, high-cost borrowing, or sale of its assets.

## VALUATION SUMMARY

We are using a DCF and a comparison analysis to help frame valuation.

### DCF

Our DCF analysis relies on a range of discount rates between 9.75% and 10.25% with a midpoint of 10.00%. This arrives at a valuation range of \$0.19 to \$0.24 with a mid-point of \$0.21.

#### Sensitivity Analysis:

Discount rate	Terminal Growth Rates				
	0%	1%	2%	3%	4%
9.50%	\$0.19	\$0.21	\$0.23	\$0.25	\$0.28
9.75%	\$0.19	\$0.20	\$0.22	\$0.24	\$0.27
10.00%	\$0.18	\$0.19	\$0.21	\$0.23	\$0.25
10.25%	\$0.17	\$0.19	\$0.20	\$0.22	\$0.24
10.50%	\$0.17	\$0.18	\$0.19	\$0.21	\$0.23

### Comparison Analysis

We believe, given the Companies updated manufacturing capabilities we can start to use a comp analysis as the comp integrates with the semiconductor industry. We use both an EV/Revenue comparison and a EV/EBITDA comparison to frame this valuation. Due to the advanced level of BLG's technology we had few public comps to choose from, however, this same technological advantage of GaN lasers vs. LEDs makes us comfortable valuing BLG at a premium to the available comps.

Company Name	Symbol	Price <sup>(1)</sup>	Mrkt Cap	EV	BV/Share	EV/Revenue <sup>(2,3)</sup>				EV/EBITDA <sup>(2,3)</sup>				
						2022	2023E	2024E	2025E	2022	2023E	2024E	2025E	
ACM Research, Inc.	ACMR	\$ 17.48	\$ 1,049.2	\$ 1,001.8	\$ 11.54	0.64x	1.79x	1.50x	1.24x	3.8x	8.9x	8.1x	6.8x	
AIXTRON SE	AIXA	\$ 30.79	\$ 3,460.0	\$ 3,242.4	\$ 6.56	5.81x	4.85x	4.46x	4.00x	24.4x	17.0x	15.2x	12.8x	
Ellipsiz Ltd	BIX	\$ 0.15	\$ 24.8	\$ (5.6)	\$ 0.48	-0.18x	N/A	N/A	N/A	-29.3x	N/A	N/A	N/A	
EEMS Italia SpA	EEMS	\$ 0.01	\$ 7.0	\$ 6.2	\$ 0.00	17.84x	N/A	N/A	N/A	-10.7x	N/A	N/A	N/A	
MKS Instruments, Inc.	MKSI	\$ 74.76	\$ 4,998.7	\$ 9,364.7	\$ 37.29	2.82x	2.56x	2.35x	2.14x	11.4x	11.7x	10.1x	8.5x	
<b>Average</b>						<b>\$ 11.17</b>	<b>5.4x</b>	<b>3.1x</b>	<b>2.8x</b>	<b>2.5x</b>	<b>-0.1x</b>	<b>12.5x</b>	<b>11.1x</b>	<b>9.4x</b>
<b>Median</b>						<b>\$ 6.56</b>	<b>2.8x</b>	<b>2.6x</b>	<b>2.4x</b>	<b>2.1x</b>	<b>3.8x</b>	<b>11.7x</b>	<b>10.1x</b>	<b>8.5x</b>
BluGlass Limited	BLG	\$ 0.03	\$ 51.2	\$ 51.3	\$ 0.01	12.1x	6.6x	4.0x	2.9x	-5.1x	-28.2x	14.9x	8.0x	

(1) Previous day's closing price

(2) Estimates are from Capital IQ

(3) Forward estimates as of calendar year

(4) All Values in USD at an exchange rate of \$1.58 AUD/USD

Source: Company reports, CapitalIQ, Stonegate Capital Partners

When using an EV/Revenue framework to inform our BLG valuation, we note that BLG is currently trading at a FY25 EV/Revenue of 2.9x compared to comps at an average of 2.5x. We are using our FY25 expected Revenue, and an EV/Revenue range of 4.0x to 5.0x with a midpoint of 4.5x. This arrives at a valuation range of A\$0.09 to A\$0.11 with a mid-point of A\$0.10.

When using an EV/EBITDA framework to inform our BLG valuation, we note that BLG is currently trading at a FY25 EV/EBITDA of 8.0x compared to comps at an average of 9.4x. We are using our FY25 expected EBITDA, and an EV/EBITDA range of 13.0x to 15.0x with a midpoint of 14.0x. This arrives at a valuation range of A\$0.10 to A\$0.11 with a mid-point of A\$0.11.

### Conclusion

To arrive at a final valuation, we give a weighting to each of the above valuation ranges. Given the lack of public comparable companies we apply a 60% weighting to our DCF analysis and a 20% weighting to our EV/EBITDA and EV/Revenue ranges. This arrives at a valuation range of A\$0.15 to A\$0.19 with a mid-point of A\$0.17. At an exchange rate of A\$1.58AUD/USD, this is equal to a range of \$0.09 to \$0.12 with a mid-point of \$0.10. Lastly, we note that BLG is trading significantly below a BV/Share of \$1.00, representing a strong case that BLG is undervalued at its current price.

EV/Revenue			
<b>CY25 E</b>	<b>4.00x</b>	<b>4.50x</b>	<b>5.00x</b>
Revenue	A\$ 28.3	A\$ 28.3	A\$ 28.3
TEV	113.3	127.5	141.7
Cash	4.3	4.3	4.3
Debt	-	-	-
Mrkt Cap	117.6	131.8	145.9
S/O	1,366.6	1,366.6	1,366.6
<b>AUD Price</b>	<b>A\$ 0.09</b>	<b>A\$ 0.10</b>	<b>A\$ 0.11</b>
<b>USD Price</b>	<b>\$ 0.05</b>	<b>\$ 0.06</b>	<b>\$ 0.07</b>

EV/EBITDA			
<b>CY25 E</b>	<b>13.00x</b>	<b>14.00x</b>	<b>15.00x</b>
Adj EBITDA	A\$ 10.1	A\$ 10.1	A\$ 10.1
TEV	131.9	142.0	152.1
Cash	4.3	4.3	4.3
Debt	-	-	-
Mrkt Cap	136.1	146.3	156.4
S/O	1,366.6	1,366.6	1,366.6
<b>AUD Price</b>	<b>A\$ 0.10</b>	<b>A\$ 0.11</b>	<b>A\$ 0.11</b>
<b>USD Price</b>	<b>\$ 0.06</b>	<b>\$ 0.07</b>	<b>\$ 0.07</b>



DISCOUNTED CASH FLOW

BluGlass Limited														
Discounted Cash Flow Model														
<i>(in \$M, except per share)</i>														
Estimates:	2022	2023	2024	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	Terminal Value
Revenue	4.3	9.5	15.7	24.9	32.8	42.6	57.5	71.9	86.2	99.2	109.1	120.0	132.0	
Operating Income	(9.4)	(11.8)	(2.9)	3.2	2.3	-	8.6	14.4	21.6	24.8	27.3	30.0	33.0	
Less: Taxes (benefit)	-	-	-	-	-	-	-	-	2.2	3.7	4.1	4.5	4.9	
NOPAT	(9.4)	(11.8)	(2.9)	3.2	2.3	-	8.6	14.4	19.4	21.1	23.2	25.5	28.0	
Plus: Depreciation & Amortization	2.3	3.9	4.2	5.5	7.0	7.0	7.0	8.0	8.0	15.0	15.0	15.0	15.0	
Plus: Changes in WC	(2.6)	(3.0)	(0.1)	(0.1)	(0.2)	(0.2)	(0.3)	(0.4)	(0.4)	(0.5)	(0.5)	(0.6)	(0.7)	
Less: Capex	(4.3)	(0.6)	(0.5)	(0.7)	(0.9)	(1.1)	(1.3)	(5.7)	(1.9)	(9.9)	(2.3)	(2.5)	(2.8)	
Free Cash Flow	(13.9)	(11.5)	0.7	7.9	8.3	5.7	14.0	16.3	25.0	25.7	35.3	37.4	39.6	505.1
Discount period - months			12	24	36	48	60	72	84	96	108	120	132	
Discount period - years			1.0	2.0	3.0	4.0	5.0	6.0	7.0	8.0	9.0	10.0	11.0	
Discount factor			0.91	0.83	0.75	0.68	0.62	0.56	0.51	0.47	0.42	0.39	0.35	
PV of FCF			0.6	6.5	6.2	3.9	8.7	9.2	12.8	12.0	15.0	14.4	13.9	177.0
<b>Growth rate assumptions:</b>														
Revenue		123.1%	65.4%	58.3%	31.4%	30.0%	35.0%	25.0%	20.0%	15.0%	10.0%	10.0%	10.0%	
Operating Income		25.6%	-74.9%	N/A	-27.2%	-100.0%	N/A	66.7%	50.0%	15.0%	10.0%	10.0%	10.0%	
EBITDA		11.6%	-116.0%	591.9%	7.3%	-24.9%	123.2%	43.2%	32.1%	34.6%	6.2%	6.5%	6.7%	
Free Cash Flow		-17.5%	-106.1%	N/A	5.5%	-31.1%	144.9%	16.1%	53.9%	2.5%	37.7%	5.8%	6.0%	
<b>Margin assumptions:</b>														
Operating Income	-219.3%	-123.4%	-18.7%	12.7%	-20.0%	0.0%	15.0%	20.0%	25.0%	25.0%	25.0%	25.0%	25.0%	
D&A as a % of sales	54.7%	41.2%	26.7%	22.1%	3.2%	2.9%	2.7%	2.5%	2.3%	2.1%	2.1%	2.1%	2.1%	
EBITDA	-164.5%	-82.3%	8.0%	34.8%	28.4%	16.4%	27.2%	31.1%	34.3%	40.1%	38.8%	37.5%	36.4%	
Taxes	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	10.0%	15.0%	15.0%	15.0%	15.0%	
Changes in WC	-61.1%	-31.9%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	-0.5%	
Capex as a % of sales	-100.2%	-6.3%	-3.0%	-2.8%	-2.6%	-2.5%	-2.3%	-8.0%	-2.3%	-10.0%	-2.1%	-2.1%	-2.1%	
<b>Valuation:</b>														
Shares outstanding	1,366.6													
PV of FCF	103.3													
PV of Terminal Value	177.0													
Enterprise Value	280.3													
less: Net Debt	(4.3)													
Estimated Total Value:	284.6													
<b>Est Equity Value/share:</b>	<b>\$0.21</b>													
Price	\$0.05													

<b>Sensitivity Analysis:</b>						
		Terminal Growth Rates				
		0%	1%	2%	3%	4%
Discount rate	9.50%	\$0.19	\$0.21	\$0.23	\$0.25	\$0.28
	9.75%	\$0.19	\$0.20	\$0.22	\$0.24	\$0.27
	10.00%	\$0.18	\$0.19	\$0.21	\$0.23	\$0.25
	10.25%	\$0.17	\$0.19	\$0.20	\$0.22	\$0.24
	10.50%	\$0.17	\$0.18	\$0.19	\$0.21	\$0.23

Source: Company Reports; Stonegate Capital Markets

BALANCE SHEET

BluGlass Limited  
 Consolidated Balance Sheets (AUD \$M)  
 Fiscal Year End: June

ASSETS	Q2 Dec-18	Q4 Jun-19	FY 2019	Q2 Dec-19	Q4 Jun-20	FY 2020	Q2 Dec-20	Q4 Jun-21	FY 2021	Q2 Dec-21	Q4 Jun-22	FY 2022	Q2 Dec-22	Q4 Jun-23	FY 2023
Cash and Cash Equivalents	11.7	6.1	6.1	3.6	5.4	5.4	4.3	4.2	4.2	6.2	5.4	5.4	3.0	4.3	4.3
Trade and Other Receivables	1.3	2.3	2.3	1.3	2.9	2.9	1.7	3.4	3.4	1.7	3.4	3.4	3.2	7.6	7.6
Inventories	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4	0.6	0.6
Other Current Assets	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.2	0.1	0.1
<b>Total Current Assets</b>	<b>13.2</b>	<b>8.6</b>	<b>8.6</b>	<b>5.2</b>	<b>8.5</b>	<b>8.5</b>	<b>6.2</b>	<b>7.7</b>	<b>7.7</b>	<b>8.2</b>	<b>8.9</b>	<b>8.9</b>	<b>6.8</b>	<b>12.5</b>	<b>12.5</b>
Property, Plant, and Equipment	2.5	5.4	5.4	7.8	7.9	7.9	6.9	5.8	5.8	5.5	11.3	11.3	10.4	8.7	8.7
Intangible Assets	8.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Security Deposit	-	-	-	-	-	-	-	-	-	-	0.3	0.3	0.4	0.5	0.5
<b>Total Assets</b>	<b>24.4</b>	<b>14.0</b>	<b>14.0</b>	<b>13.0</b>	<b>16.4</b>	<b>16.4</b>	<b>13.1</b>	<b>13.6</b>	<b>13.6</b>	<b>13.7</b>	<b>20.5</b>	<b>20.5</b>	<b>17.6</b>	<b>21.7</b>	<b>21.7</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>															
Trade and Other Payables	0.8	0.5	0.5	0.4	0.4	0.4	0.4	0.6	0.6	0.4	0.5	0.5	0.7	1.2	1.2
Lease Liabilities	-	-	-	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.7	0.7	1.0	0.8	0.8
Short Term Provisions	0.4	0.5	0.5	0.5	0.6	0.6	0.6	0.7	0.7	0.6	0.7	0.7	0.7	0.6	0.6
Borrowings	-	-	-	-	-	-	-	2.0	2.0	-	-	-	-	-	-
<b>Total Current Liabilities</b>	<b>1.2</b>	<b>1.0</b>	<b>1.0</b>	<b>1.1</b>	<b>1.2</b>	<b>1.2</b>	<b>1.2</b>	<b>3.4</b>	<b>3.4</b>	<b>1.2</b>	<b>1.9</b>	<b>1.9</b>	<b>2.4</b>	<b>2.5</b>	<b>2.5</b>
Long Term Liabilities	0.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.3	1.4	1.4	1.6	1.6	1.6
Lease Liabilities	-	-	-	1.6	1.6	1.6	1.5	1.4	1.4	1.5	3.9	3.9	3.8	3.7	3.7
<b>Total Liabilities</b>	<b>0.3</b>	<b>1.3</b>	<b>1.3</b>	<b>3.0</b>	<b>2.9</b>	<b>2.9</b>	<b>2.8</b>	<b>2.7</b>	<b>2.7</b>	<b>2.8</b>	<b>5.3</b>	<b>5.3</b>	<b>5.4</b>	<b>5.3</b>	<b>5.3</b>
Issued Capital	67.4	67.4	67.4	67.6	73.1	73.1	73.3	75.2	75.2	81.5	89.3	89.3	91.1	101.9	101.9
Reserves	(0.6)	(0.2)	(0.2)	0.2	0.9	0.9	0.9	(0.0)	(0.0)	(0.4)	0.1	0.1	0.2	(0.1)	(0.1)
Accumulates Losses	(43.8)	(55.6)	(55.6)	(58.7)	(61.6)	(61.6)	(65.1)	(67.7)	(67.7)	(71.4)	(76.2)	(76.2)	(81.5)	(87.9)	(87.9)
<b>Total Net Equity</b>	<b>22.9</b>	<b>11.6</b>	<b>11.6</b>	<b>9.0</b>	<b>12.4</b>	<b>12.4</b>	<b>9.2</b>	<b>7.5</b>	<b>7.5</b>	<b>9.6</b>	<b>13.2</b>	<b>13.2</b>	<b>9.8</b>	<b>13.9</b>	<b>13.9</b>
<b>Total Liabilities and Shareholders' Equity</b>	<b>24.4</b>	<b>14.0</b>	<b>14.0</b>	<b>13.0</b>	<b>16.4</b>	<b>16.4</b>	<b>13.1</b>	<b>13.6</b>	<b>13.6</b>	<b>13.7</b>	<b>20.5</b>	<b>20.5</b>	<b>17.6</b>	<b>21.7</b>	<b>21.7</b>

Liquidity

Current Ratio	11.1x	8.5x	8.5x	4.8x	7.4x	7.4x	5.4x	2.3x	2.3x	6.6x	4.6x	4.6x	2.8x	4.9x	4.9x
Quick Ratio	11.0x	8.4x	8.4x	4.7x	7.3x	7.3x	5.3x	2.2x	2.2x	6.5x	4.6x	4.6x	2.7x	4.7x	4.7x
Working Capital (M)	\$ 12.1	\$ 7.6	\$ 7.6	\$ 4.1	\$ 7.4	\$ 7.4	\$ 5.1	\$ 4.3	\$ 4.3	\$ 6.9	\$ 6.9	\$ 6.9	\$ 4.4	\$ 10.0	\$ 10.0

INCOME STATEMENT

BiuGlass Limited																			
Consolidated Statements of Income (in AUD \$M, except per share amounts)																			
Fiscal Year End: June																			
	FY 2018	FY 2019	FY 2020	FY 2021	Q2	Q4	FY 2022	Q2	Q4	FY 2023	Q2 E	Q4 E	FY 2024E	Q2 E	Q4 E	FY 2025E	Q2 E	Q4 E	FY 2026E
					Dec-21	Jun-22		Dec-22	Jun-23		Dec-23	Jun-24		Dec-24	Jun-25		Dec-25	Jun-26	
Revenue	\$ 0.7	\$ 0.4	\$ 0.7	\$ 0.4	\$ 0.1	\$ 0.5	\$ 0.6	\$ 0.5	\$ 0.6	\$ 1.1	\$ 1.3	\$ 1.9	\$ 3.2	\$ 4.4	\$ 4.8	\$ 9.2	\$ 7.1	\$ 8.4	\$ 15.5
Other Income	\$ 1.9	\$ 2.1	3.1	4.0	1.9	1.8	3.7	4.0	4.4	8.4	6.0	6.6	12.6	7.4	8.2	15.7	8.2	9.1	17.3
Finance Income	\$ 0.2	\$ 0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<b>Total Revenues</b>	<b>2.8</b>	<b>2.7</b>	<b>3.8</b>	<b>4.4</b>	<b>2.0</b>	<b>2.3</b>	<b>4.3</b>	<b>4.5</b>	<b>5.0</b>	<b>9.5</b>	<b>7.2</b>	<b>8.5</b>	<b>15.7</b>	<b>11.9</b>	<b>13.0</b>	<b>24.9</b>	<b>15.3</b>	<b>17.5</b>	<b>32.8</b>
Employee benefits expense	2.9	3.0	3.0	3.6	1.8	2.2	4.0	2.9	3.4	6.3	3.5	3.5	7.0	3.7	4.0	7.7	6.0	8.0	14.0
Professional fees	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.2	0.2	0.3	0.3	0.3	0.6	0.5	0.8	1.3
Board and secretarial fees	0.3	0.4	0.3	0.3	0.3	0.2	0.5	0.3	0.3	0.6	0.3	0.3	0.5	0.3	0.3	0.6	0.3	0.3	0.6
Corporate compliance & legal expense	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.2
Consultant fees	0.4	0.5	0.6	0.4	0.1	0.1	0.2	0.0	0.3	0.3	0.1	0.3	0.4	0.1	0.3	0.4	0.1	0.3	0.4
Finance cost	-	-	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.3	0.3	0.6	0.4	0.4	0.8
Office utilities	-	-	-	-	-	0.3	0.3	-	1.3	1.3	-	0.5	0.5	-	0.5	0.5	-	0.5	0.5
Rent expense	0.3	0.3	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Subscriptions	-	-	-	-	-	0.1	0.1	-	3.2	3.2	-	1.0	1.0	-	1.0	1.0	-	1.0	1.0
Travel and accommodation expenses	0.2	0.2	0.1	0.0	0.0	0.1	0.1	0.1	0.2	0.3	0.2	0.2	0.3	0.2	0.2	0.3	0.2	0.2	0.3
Consumables	1.2	1.7	1.9	3.1	2.0	1.6	3.6	3.1	(0.6)	2.5	1.2	1.4	2.6	1.5	1.4	2.9	1.5	1.4	2.9
Depreciation and amortisation	0.2	0.2	1.1	2.1	1.1	1.2	2.3	1.8	2.1	3.9	2.0	2.2	4.2	2.5	3.0	5.5	3.5	3.5	7.0
Share based payment expenses	0.1	0.7	1.2	(0.5)	0.6	0.2	0.8	0.0	0.2	0.2	-	-	-	-	-	-	-	-	-
Other expenses	0.9	9.8	1.1	1.2	0.6	0.5	1.1	1.2	0.6	1.8	0.8	0.8	1.5	0.8	0.8	1.5	0.8	0.8	1.5
<b>Total Operating Expenses</b>	<b>6.7</b>	<b>17.2</b>	<b>9.8</b>	<b>10.7</b>	<b>6.6</b>	<b>7.0</b>	<b>13.6</b>	<b>9.8</b>	<b>11.4</b>	<b>21.3</b>	<b>8.3</b>	<b>10.4</b>	<b>18.7</b>	<b>9.7</b>	<b>12.1</b>	<b>21.8</b>	<b>13.3</b>	<b>17.2</b>	<b>30.4</b>
<b>Operating Income</b>	<b>(3.8)</b>	<b>(14.4)</b>	<b>(6.0)</b>	<b>(6.3)</b>	<b>(4.6)</b>	<b>(4.7)</b>	<b>(9.4)</b>	<b>(5.4)</b>	<b>(6.4)</b>	<b>(11.8)</b>	<b>(1.1)</b>	<b>(1.9)</b>	<b>(2.9)</b>	<b>2.2</b>	<b>0.9</b>	<b>3.2</b>	<b>2.0</b>	<b>0.3</b>	<b>2.3</b>
Provision for Income Tax	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>Net Income</b>	<b>(3.8)</b>	<b>(14.4)</b>	<b>(6.0)</b>	<b>(6.3)</b>	<b>(4.6)</b>	<b>(4.7)</b>	<b>(9.4)</b>	<b>(5.4)</b>	<b>(6.4)</b>	<b>(11.8)</b>	<b>(1.1)</b>	<b>(1.9)</b>	<b>(2.9)</b>	<b>2.2</b>	<b>0.9</b>	<b>3.2</b>	<b>2.0</b>	<b>0.3</b>	<b>2.3</b>
<b>Basic EPS (Cents per share)</b>	<b>(0.99)</b>	<b>(3.45)</b>	<b>(1.27)</b>	<b>(0.87)</b>	<b>(0.47)</b>	<b>(0.45)</b>	<b>(0.89)</b>	<b>(0.42)</b>	<b>(0.47)</b>	<b>(0.86)</b>	<b>(0.08)</b>	<b>(0.13)</b>	<b>(0.21)</b>	<b>0.16</b>	<b>0.07</b>	<b>0.22</b>	<b>\$ 0.00</b>	<b>\$ 0.00</b>	<b>\$ 0.00</b>
<b>Diluted EPS (Cents per share)</b>	<b>(0.99)</b>	<b>(3.45)</b>	<b>(1.27)</b>	<b>(0.87)</b>	<b>(0.47)</b>	<b>(0.45)</b>	<b>(0.89)</b>	<b>(0.42)</b>	<b>(0.47)</b>	<b>(0.86)</b>	<b>(0.08)</b>	<b>(0.13)</b>	<b>(0.21)</b>	<b>0.16</b>	<b>0.07</b>	<b>0.22</b>	<b>\$ 0.00</b>	<b>\$ 0.00</b>	<b>\$ 0.00</b>
WTD Shares Out - Basic	389.4	418.3	473.1	724.6	989.3	1,056.8	1,056.8	1,288.5	1,366.6	1,366.6	1,391.6	1,407.6	1,399.6	1,433.4	1,449.9	1,441.6	1,476.4	1,493.4	1,484.9
WTD Shares Out - Diluted	389.4	418.3	473.1	724.6	989.3	1,056.8	1,056.8	1,288.5	1,366.6	1,366.6	1,391.6	1,407.6	1,399.6	1,433.4	1,449.9	1,441.6	1,476.4	1,493.4	1,484.9
<b>EBITDA</b>	<b>(3.6)</b>	<b>(14.2)</b>	<b>(4.9)</b>	<b>(4.2)</b>	<b>(3.5)</b>	<b>(3.5)</b>	<b>(7.0)</b>	<b>(3.6)</b>	<b>(4.2)</b>	<b>(7.8)</b>	<b>0.9</b>	<b>0.3</b>	<b>1.3</b>	<b>4.7</b>	<b>3.9</b>	<b>8.7</b>	<b>5.5</b>	<b>3.8</b>	<b>9.3</b>
<b>Adjusted EBITDA</b>	<b>\$ (3.6)</b>	<b>\$ (13.6)</b>	<b>\$ (3.6)</b>	<b>\$ (4.6)</b>	<b>\$ (2.9)</b>	<b>\$ (3.2)</b>	<b>\$ (6.1)</b>	<b>\$ (3.4)</b>	<b>\$ (3.9)</b>	<b>\$ (7.3)</b>	<b>\$ 1.0</b>	<b>\$ 0.4</b>	<b>\$ 1.5</b>	<b>\$ 5.0</b>	<b>\$ 4.2</b>	<b>\$ 9.3</b>	<b>\$ 5.9</b>	<b>\$ 4.2</b>	<b>\$ 10.1</b>

<b>Margin Analysis</b>																			
Operating Margin	-136.6%	-524.9%	-156.8%	-144.4%	-229.4%	-210.2%	-219.3%	-119.8%	-126.7%	-123.4%	-14.9%	-21.9%	-18.7%	18.8%	7.3%	12.7%	13.0%	1.8%	7.1%
EBITDA Margin	-127.8%	-493.9%	-93.8%	-105.9%	-142.4%	-141.7%	-142.0%	-76.7%	-77.5%	-77.1%	14.2%	5.1%	9.2%	42.3%	32.6%	37.2%	38.6%	24.2%	30.9%
Pre-Tax Margin	-136.6%	-524.9%	-156.8%	-144.4%	-229.4%	-210.2%	-219.3%	-119.8%	-126.7%	-123.4%	-14.9%	-21.9%	-18.7%	18.8%	7.3%	12.7%	13.0%	1.8%	7.1%
Net Income Margin	-136.6%	-524.9%	-156.8%	-144.4%	-229.4%	-210.2%	-219.3%	-119.8%	-126.7%	-123.4%	-14.9%	-21.9%	-18.7%	18.8%	7.3%	12.7%	13.0%	1.8%	7.1%
Tax Rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

<b>Growth Rate Y/Y</b>																			
Total Revenue	0.3%	-2.3%	39.1%	14.1%	-9.3%	5.2%	-2.2%	122.3%	123.9%	123.1%	61.3%	69.0%	65.4%	64.5%	53.1%	58.3%	28.7%	33.9%	31.4%
Total cost of revenues	2.9%	158.2%	-42.8%	8.6%	12.3%	47.0%	27.8%	48.3%	63.6%	56.2%	-15.7%	-9.1%	-12.1%	16.3%	16.5%	16.4%	37.7%	41.7%	40.0%
Operating Income	4.9%	275.6%	-58.4%	5.1%	25.3%	81.2%	48.5%	16.1%	34.9%	25.6%	-79.9%	-70.8%	-74.9%	-306.9%	-150.8%	-207.9%	-10.5%	-66.2%	-27.2%
Pre-Tax Income	4.9%	275.6%	-58.4%	5.1%	25.3%	81.2%	48.5%	16.1%	34.9%	25.6%	-79.9%	-70.8%	-74.9%	-306.9%	-150.8%	-207.9%	-10.5%	-66.2%	-27.2%
Net Income	4.9%	275.6%	-58.4%	5.1%	25.3%	81.2%	48.5%	16.1%	34.9%	25.6%	-79.9%	-70.8%	-74.9%	-306.9%	-150.8%	-207.9%	-10.5%	-66.2%	-27.2%

Source: Company Reports, Stonegate Capital Partners estimates

STATEMENT OF CASH FLOWS

BluGlass Limited Consolidated Cash Flow Statements (AUD \$M) Fiscal Year End: June												
CASH FLOW	Q2 Dec-19	Q4 Jun-20	FY 2020	Q2 Dec-20	Q4 Jun-21	FY 2021	Q2 Dec-21	Q4 Jun-22	FY 2022	Q2 Dec-22	Q4 Jun-23	FY 2023
<b>Operating Activities</b>												
Receipts from customers	0.5	0.2	0.7	0.2	0.1	0.4	0.1	0.5	0.6	0.6	0.5	1.1
Research and development tax rebate	1.3	1.1	2.4	1.5	1.2	2.7	3.3	-	3.3	4.0	-	4.0
Interest received	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Interest paid on lease liabilities	-	(0.1)	(0.1)	-	(0.1)	(0.1)	(0.0)	(0.1)	(0.1)	(0.1)	(0.1)	(0.2)
Government grants	-	0.2	0.2	0.5	0.1	0.7	0.3	-	0.3	0.0	-	0.0
Payents to suppliers and employees	(3.1)	(4.4)	(7.5)	(3.1)	(5.3)	(8.5)	(5.3)	(5.0)	(10.4)	(8.1)	(8.7)	(16.9)
<b>Cash flow generated/(absorbed) from operating Activities</b>	<b>(1.3)</b>	<b>(3.0)</b>	<b>(4.3)</b>	<b>(0.9)</b>	<b>(3.9)</b>	<b>(4.8)</b>	<b>(1.6)</b>	<b>(4.6)</b>	<b>(6.2)</b>	<b>(3.5)</b>	<b>(8.3)</b>	<b>(11.9)</b>
<b>Investing Activities</b>												
Payments for security deposits	-	-	-	-	-	-	-	-	-	(0.1)	(0.0)	(0.1)
Purchase of property, plant, and equipment	(1.1)	(0.6)	(1.7)	(0.1)	(0.0)	(0.1)	(0.4)	(3.9)	(4.3)	(0.4)	(0.2)	(0.6)
<b>Cash flow generated by Investing Activities</b>	<b>(1.1)</b>	<b>(0.6)</b>	<b>(1.7)</b>	<b>(0.1)</b>	<b>(0.0)</b>	<b>(0.1)</b>	<b>(0.4)</b>	<b>(3.9)</b>	<b>(4.3)</b>	<b>(0.5)</b>	<b>(0.2)</b>	<b>(0.7)</b>
<b>Financing Activities</b>												
Proceeds from issue of shares, net of cost	-	5.5	5.5	-	1.9	1.9	6.5	7.4	13.9	1.9	10.1	12.0
Transaction cost on issue of shares	-	-	-	(0.0)	0.0	-	(0.3)	0.3	-	(0.0)	0.0	-
Lease liability	(0.1)	(0.1)	(0.2)	(0.1)	(0.1)	(0.2)	(0.1)	(0.2)	(0.3)	(0.2)	(0.3)	(0.5)
Interest Paid	(0.0)	0.0	(0.0)	(0.0)	0.0	-	(0.0)	-	(0.0)	-	(0.0)	(0.0)
Proceeds from options exercised	0.0	-	0.0	-	-	-	-	-	-	-	-	-
Borrowings	-	-	-	-	2.0	2.0	(2.0)	-	(2.0)	-	-	-
<b>Cash flow generated/(absorbed) by financing Activities</b>	<b>(0.1)</b>	<b>5.5</b>	<b>5.3</b>	<b>(0.1)</b>	<b>3.8</b>	<b>3.6</b>	<b>4.1</b>	<b>7.5</b>	<b>11.6</b>	<b>1.7</b>	<b>9.7</b>	<b>11.4</b>
<b>Net Cash flow in the year</b>	<b>(2.5)</b>	<b>1.8</b>	<b>(0.7)</b>	<b>(1.1)</b>	<b>(0.1)</b>	<b>(1.3)</b>	<b>2.1</b>	<b>(0.9)</b>	<b>1.1</b>	<b>(2.3)</b>	<b>1.2</b>	<b>(1.1)</b>
<b>Cash and Cash Equivalents</b>												
Beginning Cash balance	6.1	3.6	6.1	5.4	4.3	5.4	4.2	6.2	4.2	5.4	3.0	5.4
Ending Cash balance	3.6	5.4	5.4	4.3	4.2	4.2	6.2	5.3	5.3	3.0	4.3	4.3

Source: Company Reports, Stonegate Capital Partners

## IMPORTANT DISCLOSURES AND DISCLAIMERS

The following disclosures are related to Stonegate Capital Partners (SCP) research reports.

The information used for the creation of this report has been obtained from sources we considered to be reliable, but we can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice and SCP does not undertake to advise you of any such changes. In preparing this research report, SCP analysts obtain information from a variety of sources, including to but not limited to, the issuing Company, a variety of outside sources, public filings, the principals of SCP and outside consultants. SCP and its analyst may engage outside contractors with the preparation of this report. The information contained in this report by the SCP analyst is believed to be factual, but we can neither guarantee nor represent the completeness or accuracy of the information herewith. While SCP endeavors to update the information contained herein on a reasonable basis, there may be regulatory, compliance, or other reasons that prevent us from doing so. The opinions or information expressed are believed to be accurate as of the date of this report; no subsequent publication or distribution of this report shall mean or imply that any such opinions or information remains current at any time after the date of this report. Reproduction or redistribution of this report without the expressed written consent of SCP is prohibited. Additional information on any securities mentioned is available on request. SCP does not rate the securities covered in its research. SCP does not have, nor has previously had, a rating for any securities of the Company. SCP does not have a price target for any securities of the Company.

Recipients of this report who are not market professionals or institutional investors should seek the advice of their independent financial advisor prior to making any investment decision based on this report or for any necessary explanation of its contents. Because the objectives of individual clients may vary, this report is not to be construed as an offer or the solicitation of an offer to sell or buy the securities herein mentioned. This report is the independent work of SCP and is not to be construed as having been issued by, or in any way endorsed or guaranteed by, any issuing companies of the securities mentioned herein.

SCP does not provide, nor has it received compensation for investment banking services on the securities covered in this report. SCP does not expect to receive compensation for investment banking services on the securities covered in this report. SCP has a non-exclusive Advisory Services agreement to provide research coverage, retail and institutional awareness, and overall Investor Relations support and for which it is compensated \$3,000 per month. SCP's equity affiliate, Stonegate Capital Markets (SCM) - member FINRA/SIPC - may seek to provide investment banking services on the securities covered in this report for which it could be compensated.

SCP Analysts are restricted from holding or trading securities in the issuers which they cover. Research Analyst and/or a member of the Analyst's household do not own shares of this security. Research Analyst, employees of SCP, and/or a member of the Analyst's household do not serve as an officer, director, or advisory board member of the Company. SCP and SCM do not make a market in any security, nor do they act as dealers in securities.

SCP Analysts are paid in part based on the overall profitability of SCP and SCM. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by SCP for services described above. No part of Analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article. This security is eligible for sale in one or more states. This security may be subject to the Securities and Exchange Commission's Penny Stock Rules, which may set forth sales practice requirements for certain low-priced securities.

## CONTACT INFORMATION

### Investor Relations

Stonegate Capital Partners  
500 Crescent Court-Suite 370  
Dallas, Texas 75202  
Phone: 214-987-4121  
[www.stonegateinc.com](http://www.stonegateinc.com)